ArticleMolecular oncology2015
Telomere fusion threshold identifies a poor prognostic subset of breast cancer patients.
Article in Molecular oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Shorter telomere length as a prognostic marker for survival and recurrence in breast cancer: a systematic review and meta-analysis.Exploration of targeted anti-tumor therapy · 2025Pooled it
- Telomere-driven replicative crisis is driven by large-scale changes in genomic architecture.Genome research · 2026Article
- Identification of MAPK12 as a Prognostic Biomarker for Esophageal Carcinoma Using Bioinformatics and Machine Learning.BioMed research international · 2025Article
- Prognostic model based on telomere-related genes predicts the risk of oral squamous cell carcinoma.BMC oral health · 2023Article
- Article
- High-throughput STELA provides a rapid test for the diagnosis of telomere biology disorders.Human genetics · 2021Article
- Effect of DNA repair inhibitor AsiDNA on the incidence of telomere fusion in crisis.Human molecular genetics · 2021Article
- Short Dysfunctional Telomere Is Highly Predictive of Dismal Outcome in MDS but Not in AML Patients.International journal of hematology-oncology and stem cell research · 2020Article
- Telomere alterations in neurofibromatosis type 1-associated solid tumors.Acta neuropathologica communications · 2019Article
- Telomere attrition: metabolic regulation and signalling function?Biology letters · 2019Article
- DNA Ligase 1 is an essential mediator of sister chromatid telomere fusions in G2 cell cycle phase.Nucleic acids research · 2019Article
- PARP inhibition prevents escape from a telomere-driven crisis and inhibits cell immortalisation.Oncotarget · 2018Article
- Acute telomere deprotection prevents ongoing BFB cycles and rampant instability in p16Oncotarget · 2018Article
- Telomeres and genomic evolution.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2018Review
- Telomere Length Dynamics and the Evolution of Cancer Genome Architecture.International journal of molecular sciences · 2018Review
- Maintenance of telomere length in AML.Blood advances · 2017Review
- High-throughput single-molecule telomere characterization.Genome research · 2017Article
- Telomere erosion in NF1 tumorigenesis.Oncotarget · 2017Article
- Telomeres in cancer: tumour suppression and genome instability.Nature reviews. Molecular cell biology · 2017Review
- Extensive telomere erosion is consistent with localised clonal expansions in Barrett's metaplasia.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Telomere dysfunction and fusion can drive genomic instability and clonal evolution in human tumours, including breast cancer. Telomere length is a critical determinant of telomere function and has been evaluated as a prognostic marker in several tumour types, but it has yet to be used in the clinical setting. Here we show that high-resolution telomere length analysis, together with a specific telomere fusion threshold, is highly prognostic for overall survival in a cohort of patients diagnosed with invasive ductal carcinoma of the breast (n = 120). The telomere fusion threshold defined a small subset of patients with an extremely poor clinical outcome, with a median survival of less than 12 months (HR = 21.4 (7.9-57.6), P < 0.0001). Furthermore, this telomere length threshold was independent of ER, PGR, HER2 status, NPI, or grade and was the dominant variable in multivariate analysis. We conclude that the fusogenic telomere length threshold provides a powerful, independent prognostic marker with clinical utility in breast cancer. Larger prospective studies are now required to determine the optimal way to incorporate high-resolution telomere length analysis into multivariate prognostic algorithms for patients diagnosed with breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.